SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII)
NTII 0.00010000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: btd who wrote (220)1/17/1998 12:37:00 AM
From: John Dwyer  Read Replies (2) of 1494
 
Good news on the Memantine trial will almost certainly boost the
stock price over $1. However, they are also in violation because
they failed to meet the tangible asset requirements. So these
extensions are meaningless unless they get an infusion of cash,
right? I expected NTII to partner if results were good but this
suggests that they have some kind of deal close. Either a partner
for Memantine or perhaps they are out-licensing Dynorphine. They
must be telling NASDAQ something good...

John
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News